Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Why is Roche optimally qualified to develop microarrays for diagnostic use?

April 26, 2017develop diagnostic microarrays optimally qualified Roche

0

Posted

Why is Roche optimally qualified to develop microarrays for diagnostic use?

1 Answer

0

Posted

Roche Diagnostics has proven its ability to develop pioneering and innovative diagnostic tools and tests that shape the healthcare industry and create new markets. Now, Roche Diagnostics is the first company to develop Affymetrix’s microarray (“chip”) technology for diagnostic applications. Our new AmpliChip product line is being designed to enable comprehensive analysis of complex genomic information in a single assay. Previously, such analyses were either not feasible for routine clinical applications or were done for research applications using highly manual and time-consuming methods.